MedPath

Body Impedance Analysis to Detect ICUAW

Completed
Conditions
Critical Illness
Interventions
Diagnostic Test: Body Impedance Analysis
Registration Number
NCT05572138
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

The aim of the study is to detect a value of muscle and organ mass measured by body impedance analysis and its correlation with the Medical Research Council (MRC) score. An MRC score ≤ 48 is defined as a diagnosis of ICU acquired weakness. The correlation of the values detected by BIA and their transfer to an MRC Score ≤ 48 will be investigated.

The knowledge gained will be used for early detection of ICUAW in order to reduce the consequences of the same.

Detailed Description

Intensive Care Unit Acquired Weakness (ICUAW) describes the clinically diagnosed manifestation of neuromuscular organ dysfunction. It develops in approximately 40% of all ICU patients, which corresponds to at least 1.2 million patients annually in Germany. All these patients face a wide spectrum of sequelae and increased mortality up to 5 years after ICU discharge. A characteristic pathophysiological phenomenon is early severe muscle atrophy, which is as high as 17% in the first days after ICU admission.

ICUAW is currently diagnosed by the MRC score, which is assessed by the sum of manual muscle strength test results in 12 muscle groups (sum score). Manual muscle testing (MMT) is not possible during the early phase in critical illness in most patients due to coma, delirium, and/or injury. In addition, there is a possible discrepancy by different observers. As a result, early detection of ICUAW may be inadequate in most patients and unreliable during critical illness.

Measurement by BIA is reproducible, so differences in measurement can be attributed to changes in clinical condition. Body impedance analysis thus demonstrates a means of objective measurement.

Thus, the study aims to counteract the long-term consequences of ICUAW through early detection of ICUAW by allowing countermeasures to be taken earlier.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
62
Inclusion Criteria
  • Patients aged ≥ 18 years with ventilatory support within 36 hours from ICU admission.
Exclusion Criteria
  • With a language barrier
  • Patients with pacemaker or other electronic implant
  • Expected death or discontinuation of life-sustaining measures.
  • Not walking independently before hospitalization (gait aids allowed)
  • Allergy to electrode gel
  • BIA or ultrasound not technically feasible due to e.g. extensive wounds, skin rash or bandages

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Critically ill patientsBody Impedance Analysis-
Primary Outcome Measures
NameTimeMethod
Correlation: Skeletal muscle mass and MRC-Scoretill Day 30

The primary endpoint is the correlation between Skeletal muscle mass (SMM) measured by BIA and MRC score.

Secondary Outcome Measures
NameTimeMethod
Hospital mortalitytill Day 30

Mortality during Hospital stay

in-hospital mortalitytill Day 30 (till hospital discharge)

Mortality during the Hospital stay

Correlation CSA and Skeletal muscle masstill Day 30

Cross sectional area of muscle ultrasound (M. rectus femoris) and Skeletal muscle mass (SMM) measured by BIA

ICU-LOStill Day 30 (till ICU discharge)

Length of stay in the ICU

Kreatinin : MRC correlationtill Day 30

Correlation of creatinine in blood with MRC score.

IMS during the ICU staytill Day 30 or ICU discharge

achieved mobilization level during the ICU stay using the ICU Mobility Scale (IMS)

UCR : MRC correlationtill Day 30

Correlation of urea-creatinine ratio in blood with MRC score.

ICU mortalitytill Day 30

Mortality during ICU stay

Duration of Mechanical ventilationtill Day 30

Duration of invasive mechanical ventilator dependency

Hospital LOStill Day 30 (till hospital discharge)

Length of stay in the hospital

Trial Locations

Locations (1)

Charité - Univiversitätsmedizin Berlin

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath